VITROS® SARS-CoV-2 Antigen Test
✔ High throughput
✔ Highly accurate
✔ Quick results
This lab-based antigen test provides health care systems and communities more capacity to diagnose individuals quickly and accurately with an active SARS-CoV-2 infection. The test is a laboratory immunoassay for the in-vitro qualitative detection of the SARS-CoV-2 nucleocapsid antigen.*
- Capacity to run up to 130 tests per hour on our VITROS® XT 7600 and 5600 Integrated Systems and VITROS® 3600 Immunodiagnostic System
- Excellent specificity and sensitivity, making it a viable alternative to PCR testing**
- Results are reported as either reactive (positive) or non-reactive (negative) with no gray zone
- Simple sample preparation for swabs placed in a viral transport medium†,‡
- Can be run alongside other IVD tests needed for routine testing or patient management
*Available only in the U.S. market under Emergency Use Authorization with the U.S. Food and Drug Administration. Availability of assays varies by country.
**Refer to country-specific VITROS® Immunodiagnostic Products SARS-CoV-2 Antigen Instructions for Use for sensitivity and specificity performance data and intended use.
†For symptomatic individuals, specimens are to be collected using nasopharyngeal and nasal swabs.
‡Asymptomatic use is subject to regulatory approval outside the U.S.
The role of high-throughput antigen testing during a pandemic
The COVID-19 pandemic has challenged the health care community to consider testing strategies that will support critical public health initiatives to detect the spread of SARS-CoV-2. Critical response time, scalability and accuracy are key. High-throughput antigen testing has received attention for its ability to test high volumes quickly.